Kenneth A. Burdick

October 10, 2026

Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.

October 17, 2026

Centene Expands CHOICE Arrangements in Indiana, Ohio, Oklahoma. Centene has rolled out new benefit programs that support its CHOICE arrangements in Indiana, Ohio and Oklahoma, signaling a push to broaden its managed care footprint. Analysts note the company’s turnaround still has room to grow, and its target price remains well above the current level. The broader managed‑care landscape is also shifting, with UnitedHealth reporting higher margins but lower membership, a trend that may influence competitive dynamics.

October 4, 2026

Evercore and Wells Fargo Lower FHN Price Targets to $25. Evercore ISI and Wells Fargo recently lowered their price targets for First Horizon to $25, citing concerns about the bank's net interest income in a rising rate environment. These updates align with the stock trading near its 52-week low, reflecting cautious sentiment among analysts. The average analyst target remains at $27.69, but the recent cuts indicate a more conservative outlook for the near term.